Trial · NCT05370807
A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma
NCT05370807, Phase 2, Active not recruiting, Universitair Ziekenhuis Brussel
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma. Trials, record NCT05370807. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05370807
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma
- NCT number
- NCT05370807
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 48 participants, estimated
- Lead sponsor
- Universitair Ziekenhuis Brussel
- Conditions
- Melanoma Stage III, Melanoma Stage IV
- Interventions
- Regorafenib 40 MG Oral Tablet, Triplet therapy
- First posted
- 2022-05-12
- Last updated
- 2026-09-30
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To measure the anti-tumor acitivity of regorafenib treatment in patients with advanced pretreated melanoma. | Through study completion, an average of 1 year. | Objective response rate (ORR; defined as the percentage of subjects with a confirmed complete response \[CR\] or partial response \[PR\] at any time per Response Evaluation Criteria in Solid Tumors \[RECIST\], version 1.1 |
| Secondary | To measure the progression-free survival (PFS) of study patients treated with regorafenib | Through study completion, an average of 1 year. | Progression-free survival (PFS; defined as the time from the date of the first dose administration of regorafenib until the earliest date of documented disease progression \[per RECIST v1.1\] or death due to any cause) |
| Secondary | To measure the overall survival (OS) of study patients treated with regorafenib | Through study completion, an average of 1 year. | overall survival (OS; defined as the time from the date of the first dose administration of regorafenib until the date of death due to any cause) |
| Secondary | Number of AE in study patients | Through study completion, an average of 1 year. | To count the number of Adverse Events study patients have during the study. |
| Secondary | To measure the severity of AE in study patients | Through study completion, an average of 1 year. | Document the grade of all AE in study patients, expressed in grade 1 Mild, 2 Moderate, 3 Severe, 4 Life-Threatening, 5 Death related to AE |
| Secondary | To measure the Health-Related Quality of Life | Through study completion, an average of 1 year. | There will be 1 questionnaire used to assess the quality of life. The generic health status of the patients will be assessed by means of the EuroQOL-5D-3L (EQ-5D-3L). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05370807
GET https://conductscience.org/api/trials/v1/NCT05370807/registered